Nanoform’s final clinical results confirm value proposition to the pharma industry
Press release Nanoform Finland Plc May 18, 2021 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform’s final clinical results confirm value proposition to the pharma industry Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced the completion and final results of its clinical study. The primary, secondary and optional exploratory objectives of the study were all met. The results show that Nanoform’s CESS[®] technology enabled development of a fast-acting piroxicam immediate release (IR) tablet